Sopharma Trading AD (XBUL:SFT) ROCE %: 23.51% (As of Mar. 2026)


XBUL:SFT Sopharma Trading AD XBUL:SFT
82 GF Score
Price €2.90
GF Value €7.62
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sopharma Trading AD ROCE %?

Sopharma Trading AD XBUL:SFT -3.33% 82 ROCE % is 23.51% as of Mar. 2026. GuruFocus rates XBUL:SFT with a GF Score™ of 82/100 and a GF Value™ of €7.62 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sopharma Trading AD's annualized ROCE % for the quarter that ended in Mar. 2026 was 23.51%.

Sopharma Trading AD  (XBUL:SFT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sopharma Trading AD ROCE % Related Terms

Sopharma Trading AD ROCE % Historical Data

* Premium members only.

The historical data trend for Sopharma Trading AD's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma Trading AD ROCE % Chart

Sopharma Trading AD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.33 9.32 21.27 22.81 26.20

Sopharma Trading AD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.92 27.13 19.94 16.52 23.51
XBUL:SFT
82GF Score
Sopharma Trading AD XBUL:SFT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma Trading AD ROCE % Calculation

Sopharma Trading AD's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=41.975/( ( (408.842 - 261.243) + (477.684 - 304.888) )/ 2 )
=41.975/( (147.599+172.796)/ 2 )
=41.975/160.1975
=26.20 %

Sopharma Trading AD's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=42.42/( ( (477.684 - 304.888) + (484.036 - 295.974) )/ 2 )
=42.42/( ( 172.796 + 188.062 )/ 2 )
=42.42/180.429
=23.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 23.51% mean?
Sopharma Trading AD (XBUL:SFT) has a ROCE % of 23.51% as of Mar. 2026.
Is Sopharma Trading AD's ROCE % too high?
Sopharma Trading AD's current ROCE % is 23.51%. The Medical Distribution industry median ROCE % is 8.92. Sopharma Trading AD's value of 23.51% is 163.6% above this industry median. Overall, Sopharma Trading AD has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's ROCE % compare to MCK and CAH?
Sopharma Trading AD's ROCE % of 23.51% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. Sopharma Trading AD's value of 23.51% is 163.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current ROCE % of 23.51% is 163.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current ROCE % is 23.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.62, compared to a current price of €2.90 — trading 61.9% below its estimated fair value. The current ROCE % is 23.51% and 163.6% above the Medical Distribution industry median of 8.92. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current ROCE % is 23.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued. The current stock price of €2.90 is trading 61.9% below its estimated GF Value™ of €7.62. GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.

Key valuation signals for XBUL:SFT:

  • ROCE %: 23.51%
  • GF Value™: €7.62 vs. price of €2.90 (61.9% below fair value)
  • GF Score™: 82/100 with 2 warning signs
  • Industry Position: 163.6% above the Medical Distribution median

No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma Trading AD Business Description

Address Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score

Get the complete analysis for XBUL:SFT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.90
Price
€7.62
GF Value